Clinical Significance Of BRAF V600E Mutation And RASSF1A Methylation In Papillary Thyroid Cancer

ObjectiveTo study the BRAF V600E mutation and RASSF1A methylation in PTC and benign thyroid lesions,analyze the correlation between clinicopathological parameters of PTC and BRAF V600E mutation and RASSF1A methylation,as well as the correlation between them in PTC,and explore their significance in the pathogenesis,diagnosis and prognosis of PTC.Methods27 cases of PTC tissue samples from January 2019 to December 2019 were collected as the research objects,and 27 cases of benign thyroid lesions tissue samples from the same period were selected as the control group.The BRAF V600E mutation in 27 cases of PTC and 27 cases of benign thyroid lesions was detected by PCR-based Sanger sequencing,and the RASSF1A methylation in 27 cases of PTC and 27 cases of benign thyroid lesions was detected by quantitative methylation specific PCR(qMSP).Results1.The mutation rate of BRAF V600E was 48.1%(13/27)in PTC,3.7%(1/27)in benign thyroid lesions;the methylation rate of RASSF1A was 85.2%(23/27)in PTC,92.6%(25/27)in benign thyroid lesions,88.9%(8/9)in thyroid adenoma and 94.4%(17/18)in nodular goiter.2.The mutation rate of BRAF V600E in PTC was significantly higher than that in benign thyroid lesions(P<0.05).BRAF V600E mutation was associated with lymph node metastasis(P<0.05),but not with gender,age,tumor diameter,extraglandular invasion and clinical stage of tumor(P>0.05).3.There was no significant difference in the methylation rate of RASSF1A between PTC and benign thyroid lesions(P>0.05).RASSF1A methylation was not associated with gender,age,tumor diameter,lymph node metastasis,extraglandular invasion and clinical stage of tumor(P>0.05).4.There was no correlation between BRAF V600E mutation and RASSF1A methylation in PTC(r=-0.015,P>0.05).Conclusion1.BRAF V600E mutation is specifically expressed in PTC,which has a certain clinical value in differentiating PTC from benign thyroid diseases.2.BRAF V600E mutation is related to the clinical progress of PTC,and may be involved in the malignant evolution of PTC.3.RASSF1A methylation is not associated with the occurrence and development of PTC.